Attention deficit hyperactivity disorder

ADHD Online Launches Medication Management in its Home State of Michigan

Retrieved on: 
Tuesday, October 5, 2021
Online, ADHD, CEO, Attention deficit hyperactivity disorder, Patient, Michigander, Hope, Diagnosis, MD, Health insurance

GRAND RAPIDS, Mich., Oct. 5, 2021 /PRNewswire/ -- ADHD Online , a leader in telehealth diagnosis and treatment for attention deficit hyperactivity disorder (ADHD), now offers medication management in the organization's home state of Michigan.

Key Points: 
  • GRAND RAPIDS, Mich., Oct. 5, 2021 /PRNewswire/ -- ADHD Online , a leader in telehealth diagnosis and treatment for attention deficit hyperactivity disorder (ADHD), now offers medication management in the organization's home state of Michigan.
  • In addition to an ADHD diagnosis, residents in Michigan can now receive prescription medication from ADHD Online's network of medical providers.
  • The Michigan rollout follows the launch of medication management in California and a record-breaking number of patient interactions last month.
  • Today, we are thrilled to begin offering medication management in our own backyard," said Zach Booker, CEO at ADHD Online.

University of Rochester Researchers Link Chemo Brain to Lymphoma; Exercise Might Help Some Cancer Patients

Retrieved on: 
Tuesday, October 5, 2021
Attention, News, Strathcona County, Breast, Man, Exercise, National Cancer Institute, Memory, Cancer, Government budget balance, Solution, Survivor, Attention deficit hyperactivity disorder, Multimedia, Patient, Cognition, University of Rochester Medical Center, JNCI, Lymphoma, University, Woman, Control, Disease, Risk, Journal, Research, Brain, NCI, Amnesia, Journal of the National Cancer Institute, Breast cancer, American Journal of Clinical Oncology, Medical imaging, Toy

Separately, investigators found that routine exercise prior to chemotherapy might prevent chemo brain among women with breast cancer, according to two recently published studies by the Wilmot Cancer Institute at the University of Rochester Medical Center .

Key Points: 
  • Separately, investigators found that routine exercise prior to chemotherapy might prevent chemo brain among women with breast cancer, according to two recently published studies by the Wilmot Cancer Institute at the University of Rochester Medical Center .
  • The National Cancer Institute estimates there are 17 million survivors today and expect 22 million by 2030.
  • Until now, most chemo brain research was focused on solid tumors, such as breast and prostate cancer.
  • A primary goal is to find ways to help older adults, who in general have the highest risk for cancer.

Global Attention Deficit Hyperactivity Disorder Market 2021 - Develop In-depth Knowledge of Competition and Markets - ResearchAndMarkets.com

Retrieved on: 
Monday, September 27, 2021
Mental Health, Health, Research, G7, Attention, Epidemiology, Patient, Prevalence, Attention deficit hyperactivity disorder, Competitive landscape, Pharmaceutical industry

The "Global Attention Deficit Hyperactivity Disorder Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Attention Deficit Hyperactivity Disorder Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights into Attention Deficit Hyperactivity Disorder pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following - Attention Deficit Hyperactivity Disorder treatment options, Attention Deficit Hyperactivity Disorder late-stage clinical trials pipeline, Attention Deficit Hyperactivity Disorder prevalence by countries, Attention Deficit Hyperactivity Disorder market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Attention Deficit Hyperactivity Disorder pipeline: Find out drugs in clinical trials for the treatment of Attention Deficit Hyperactivity Disorder by development phase 3, phase 2, by pharmacological class and company
    Attention Deficit Hyperactivity Disorder epidemiology: Find out the number of patients diagnosed (prevalence) with Attention Deficit Hyperactivity Disorder by countries
    Attention Deficit Hyperactivity Disorder drugs: Identify key drugs marketed and prescribed for Attention Deficit Hyperactivity Disorder in the US, including trade name, molecule name, and company
    Attention Deficit Hyperactivity Disorder drugs sales: Find out the sales value for Attention Deficit Hyperactivity Disorder drugs by countries
    Attention Deficit Hyperactivity Disorder market valuations: Find out the market size for Attention Deficit Hyperactivity Disorder drugs in 2020 by countries.

KemPharm to Present at the Benzinga Healthcare Small Cap Conference

Retrieved on: 
Monday, September 27, 2021
ADHD, CNS, Hydrocodone, Idiopathic hypersomnia, SDX, FDA, Investor relations, Paracetamol, LinkedIn, YouTube, SUD, Twitter, Benzhydrocodone, Attention deficit hyperactivity disorder, IH, Technology, Facebook, Ligand, Audit, Pharmaceutical industry

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT (Ligand Activated Therapy) technology.

Key Points: 
  • KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT (Ligand Activated Therapy) technology.
  • KemPharm utilizes its proprietary LAT technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.
  • KemPharms lead clinical development candidate for the treatment of SUD, KP879, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate (SDX).
  • For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter , LinkedIn , Facebook and YouTube .

KemPharm to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

Retrieved on: 
Thursday, September 23, 2021
ADHD, CNS, Hydrocodone, Idiopathic hypersomnia, SDX, FDA, Investor relations, Paracetamol, LinkedIn, YouTube, SUD, Twitter, Benzhydrocodone, Attention deficit hyperactivity disorder, IH, Technology, Facebook, Ligand, Pharmaceutical industry

Dr. Mickle and members of the KemPharm management team will host virtual one-on-one meetings with registered investors and pharmaceutical company executives.

Key Points: 
  • Dr. Mickle and members of the KemPharm management team will host virtual one-on-one meetings with registered investors and pharmaceutical company executives.
  • Investors may register for the event by using the webcast link provided above, or by contacting their Cantor Fitzgerald sales representative.
  • KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT (Ligand Activated Therapy) technology.
  • For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter , LinkedIn , Facebook and YouTube .

Europe Attention Deficit Hyperactivity Disorder Market Report 2021: Pipeline, Epidemiology, Valuations, Drug Sales, and Market Shares 2018-2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 15, 2021
Pharmaceutical, Health, Mental Health, Attention, Attention deficit hyperactivity disorder, Patient, Epidemiology, Research, Competitive landscape, Prevalence, Pharmaceutical industry

The "Europe Attention Deficit Hyperactivity Disorder Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Attention Deficit Hyperactivity Disorder Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Europe Attention Deficit Hyperactivity Disorder Market and Competitive Landscape - 2021, provides comprehensive insights into Attention Deficit Hyperactivity Disorder pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following - Attention Deficit Hyperactivity Disorder treatment options, Attention Deficit Hyperactivity Disorder late-stage clinical trials pipeline, Attention Deficit Hyperactivity Disorder prevalence by countries, Attention Deficit Hyperactivity Disorder market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Attention Deficit Hyperactivity Disorder pipeline: Find out drugs in clinical trials for the treatment of Attention Deficit Hyperactivity Disorder by development phase 3, phase 2, by pharmacological class and company
    Attention Deficit Hyperactivity Disorder epidemiology: Find out the number of patients diagnosed (prevalence) with Attention Deficit Hyperactivity Disorder by countries
    Attention Deficit Hyperactivity Disorder drugs: Identify key drugs marketed and prescribed for Attention Deficit Hyperactivity Disorder in the US, including trade name, molecule name, and company
    Attention Deficit Hyperactivity Disorder drugs sales: Find out the sales value for Attention Deficit Hyperactivity Disorder drugs by countries
    Attention Deficit Hyperactivity Disorder market valuations: Find out the market size for Attention Deficit Hyperactivity Disorder drugs in 2020 by countries.

KemPharm to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

Retrieved on: 
Thursday, September 9, 2021

KemPharm utilizes its proprietary LAT technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.

Key Points: 
  • KemPharm utilizes its proprietary LAT technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.
  • KemPharms prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, stimulant use disorder (SUD) and CNS rare diseases, including idiopathic hypersomnia (IH).
  • KemPharms lead clinical development candidate for the treatment of SUD, KP879, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate (SDX).
  • For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter , LinkedIn , Facebook and YouTube .

Ehave Announces Update On Ehave Medical App With The Launch Of Covid Vaccine Passport Going Live Shortly

Retrieved on: 
Tuesday, September 7, 2021

Ehave's Covid Passport will allow individuals and small businesses to easily access vaccination verification to ease implementing new safety precautions.

Key Points: 
  • Ehave's Covid Passport will allow individuals and small businesses to easily access vaccination verification to ease implementing new safety precautions.
  • Ehaves suite of products will become live in our medical app as we complete beta testing on each individual application.
  • Mr. Kaplan continued, "Ehave's Covid Passport is an ideal scenario for individuals who want a Vaccine Passport to safely store their vaccine information and the answer for employers to track employee vaccination."
  • In addition to its Covid Vaccine Passport, Ehave is pleased to provide updates on the progress of its other products.

Supernus Announces Qelbree™ sNDA for Adult Indication Accepted for Review by FDA

Retrieved on: 
Thursday, September 2, 2021
Private Securities Litigation Reform Act, Patient, PDUFA, Attention deficit hyperactivity disorder predominantly inattentive, Boxed warning, Attention deficit hyperactivity disorder, Central nervous system, Central nervous system disease, U.S. Securities and Exchange Commission, MAOI, Shanda, Torticollis, Child, Security (finance), Nasdaq, Government, Securities Exchange Act of 1934, Parent, Prescription, Section 13, Company, Physician, Migraine, Clinical Global Impression, Adult, Safety, Behavior, FDA, Risk, CNS, CEO, Depression, Phase, Growth, GLOBE, Epilepsy, ADHD, Food, Family, Regulation of tobacco by the U.S. Food and Drug Administration, Pharmaceutical industry

The sNDA is now considered filed, with a user fee goal date (PDUFA date) of April 29, 2022.

Key Points: 
  • The sNDA is now considered filed, with a user fee goal date (PDUFA date) of April 29, 2022.
  • In December 2020, Supernus announced positive topline results from a Phase III study of Qelbree in adults for the treatment of attention deficit hyperactivity disorder (ADHD).
  • Jack Khattar, President and CEO of Supernus, said, We look forward to making Qelbree available to adult patients, if approved by the FDA.
  • Approximately 10 million adults in the U.S. have ADHD, and every adult who has ADHD had it as a child.

ADHD Online Launches Medication Management in California

Retrieved on: 
Thursday, September 2, 2021
Online, Patient, Diagnosis, CEO, Physician, Pharmacy, Hope, Attention deficit hyperactivity disorder, ADHD, MD, Cognitive behavioral therapy, Medical device, Health insurance, Hospital

GRAND RAPIDS, Mich., Sept. 2, 2021 /PRNewswire/ -- ADHD Online , a leader in telehealth diagnosis and treatment for attention deficit hyperactivity disorder (ADHD), now offers medication management in California.

Key Points: 
  • GRAND RAPIDS, Mich., Sept. 2, 2021 /PRNewswire/ -- ADHD Online , a leader in telehealth diagnosis and treatment for attention deficit hyperactivity disorder (ADHD), now offers medication management in California.
  • In addition to diagnosis, residents in California can now receive ADHD treatment plans through ADHD Online's telehealth solution.
  • In addition to medication management, ADHD Online offers virtual counseling, accommodation form completion, cognitive behavioral therapy, and many other ADHD treatment options.
  • ADHD Online's network of board-certified physicians and psychologists can prescribe medication directly to a patient's pharmacy through online visits.